HXL – Hexima Restricted | Aussie Inventory Boards

Date:


Hexima Restricted is a biotechnology corporate actively engaged within the analysis and construction of plant-derived defensin peptides for programs as human therapeutics.

Its lead product candidate, HXP124 carried out in a topical components, is a possible new prescription remedy for toenail fungal infections (or onychomycosis). Hexima is these days accomplishing a 132 affected person Australian section IIb medical trial of HXP124 for onychomycosis. Hexima holds granted, long-life patents protective HXP124 in primary markets globally.

Hexima is primarily based in Melbourne, Australia.

It’s expected that HXL will listing at the ASX throughout December 2020.

 



Source_link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Popular

More like this
Related